Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Operating Leases: 2019-2021

Historic Operating Leases for Neurocrine Biosciences (NBIX) over the last 3 years, with Sep 2021 value amounting to $121.9 million.

  • Neurocrine Biosciences' Operating Leases rose 31.50% to $121.9 million in Q3 2021 from the same period last year, while for Sep 2021 it was $121.9 million, marking a year-over-year increase of 31.50%. This contributed to the annual value of $94.4 million for FY2020, which is 8.88% up from last year.
  • Neurocrine Biosciences' Operating Leases amounted to $121.9 million in Q3 2021, which was down 1.69% from $124.0 million recorded in Q2 2021.
  • In the past 5 years, Neurocrine Biosciences' Operating Leases registered a high of $124.0 million during Q2 2021, and its lowest value of $66.2 million during Q2 2019.
  • Moreover, its 3-year median value for Operating Leases was $92.7 million (2020), whereas its average is $93.3 million.
  • Data for Neurocrine Biosciences' Operating Leases shows a peak YoY skyrocketed of 41.27% (in 2020) over the last 5 years.
  • Neurocrine Biosciences' Operating Leases (Quarterly) stood at $86.7 million in 2019, then grew by 8.88% to $94.4 million in 2020, then surged by 31.50% to $121.9 million in 2021.
  • Its Operating Leases stands at $121.9 million for Q3 2021, versus $124.0 million for Q2 2021 and $119.7 million for Q1 2021.